Review Article
Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers
Table 1
Selected clinical
trials of erlotinib. NSCLC, Non-small
cell lung cancer; OS, overall survival; ORR, overall response
rate.
| | Malignancy | Regimen | Number of patients | Results | Comments |
| | NSCLC | Erlotinib vs. placebo
[14] | 731 pts
Stage IIIB/IV NSCLC after
failure with first-line or second-line chemotherapy | Erlotinib: ORR (8.9%)
OS (6.7 mo) Placebo:
ORR (<1%) OS (4.7 mo) | Significant improvement in OS
() |
| | NSCLC | Carboplatin, Paclitaxel +/
Erlotinib
[11] | 1059 pts
Previously untreated stage
IIIB/IV NSCLC | Erolotinib: ORR (21.5%)
OS (10.6 mo) Placebo:
ORR (19.3%) OS (10.5 mo) | No difference in ORR or OS
with the combination of Erlotinib and chemotherapy |
| | Pancreatic cancer | Gemcitibine, Erlotinib vs.
placebo
[15] | 569 pts
Unresectable, locally advanced
or metastatic pancreatic cancer | Erlotinib: OS (6.2 mo)
Placebo: OS (5.9 mo) | One year survival was greater
with erlotinib plus gemcitabine (23% vs. 17%; ) |
|
|
